Medtronic to Acquire Scientia Vascular for $550 Million

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal

January 16, 2026

Healthcare Services

Boston Scientific signed a definitive agreement to acquire Penumbra, Inc. for about $14.5 billion (enterprise value) in a cash-and-stock transaction. The deal is intended to expand Boston Scientific’s cardiovascular franchise and create a scaled position in mechanical thrombectomy and adjacent neurovascular markets, and is expected to close in 2026 subject to shareholder and regulatory approvals.

Boston Scientific Acquires Axonics, Inc.

November 15, 2024

Medical Devices

Boston Scientific agreed to acquire Axonics, a medical technology company focused on urinary and bowel dysfunction, for $71 per share in cash, valuing the equity at approximately $3.7 billion. The boards approved the transaction, which was expected to close in the first half of 2024, and Boston Scientific later announced the acquisition closed on November 15, 2024.

Boston Scientific Acquires Valencia Technologies

January 12, 2026

Medical Devices

Boston Scientific acquired Valencia Technologies to advance its urology and pelvic health portfolio, adding Valencia’s implantable tibial nerve stimulation technology. The deal is expected to close in the first half of 2026, with financial terms undisclosed.

Boston Scientific to Acquire SoniVie Ltd

March 3, 2025

Medical Devices

Boston Scientific Corporation has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company developing the TIVUS intravascular ultrasound system for renal denervation therapy for hypertension. The deal includes an upfront payment of approximately $360 million for the 90% stake Boston Scientific does not already own, plus up to $180 million contingent on achievement of a regulatory milestone.

Surmodics Acquires Vetex Medical Limited

July 6, 2021

Medical Devices

Surmodics, Inc. (NASDAQ: SRDX) acquired Galway-based Vetex Medical Limited to expand its thrombectomy portfolio with the ReVene Thrombectomy Catheter. The deal included an upfront payment of $39.9 million and up to $7 million in additional milestone payments (with $3.5 million guaranteed), giving Surmodics a second FDA 510(k)-cleared mechanical thrombectomy device and IP to accelerate its thrombectomy platform development.

Vertex Pharmaceuticals Acquires ViaCyte for $320M

July 11, 2022

Biotechnology

Vertex Pharmaceuticals agreed to acquire clinical-stage cell therapy company ViaCyte for $320 million in cash. The deal gives Vertex additional stem cell lines, IP and GMP manufacturing capabilities intended to accelerate its VX-880 and other cell replacement therapy programs for type 1 diabetes.